The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study.

BMC Cancer · 2025 · PMC12284996 · PMID 40696299

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

Interestingly, although the levels of CA 19 − 9 after surgery were not significantly associated statistically with both recurrence and survival, the results showed a trend towards affecting the outcomes [DFS: HR: 2.00, 95% Confidence Interval (CI): 0.98–4.10, p = 0.058; OS: HR: 1.94, 95% Confidence Interval (CI): 0.89–4.22, p = 0.094] (Table 2 ).

also in 26,766 other papers

a favorable trendno p-value reported

There was also a favorable trend in overall survival in the GS combination group, but still no statistical significance ( p = 0.517).

also in 907 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.